Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) has earned a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last […]